256 related articles for article (PubMed ID: 36115003)
1. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
[TBL] [Abstract][Full Text] [Related]
3. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
4. Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets.
Jang M; Simoens S; Kwon T
BioDrugs; 2021 Jan; 35(1):89-101. PubMed ID: 33368051
[TBL] [Abstract][Full Text] [Related]
5. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab.
Horn DM; Alpert AE; Duggan MG; Garcia NA; Jacobson M
JCO Oncol Pract; 2023 Apr; 19(4):e476-e483. PubMed ID: 36638330
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China.
Deng W; Hu J; Li M; Yang S; Xie Z; Chen J
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1117-1126. PubMed ID: 35899310
[TBL] [Abstract][Full Text] [Related]
9. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
[TBL] [Abstract][Full Text] [Related]
10. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):743-756. PubMed ID: 34003067
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
[TBL] [Abstract][Full Text] [Related]
12. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.
McBride A; Alrawashdh N; MacDonald K; Abraham I
Future Oncol; 2022 Jan; 18(3):363-373. PubMed ID: 34747185
[TBL] [Abstract][Full Text] [Related]
13. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
Hara F; Tajima K; Tanabe K
Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer.
Muñoz C; Tai X; Arias J; Eisen A; Chaudhry M; Gavura S; Chan KKW
Curr Oncol; 2024 Mar; 31(3):1633-1644. PubMed ID: 38534957
[No Abstract] [Full Text] [Related]
15. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Jackisch C; Lammers P; Jacobs I
Breast; 2017 Apr; 32():199-216. PubMed ID: 28236776
[TBL] [Abstract][Full Text] [Related]
16. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
[TBL] [Abstract][Full Text] [Related]
17. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Paplomata E; Nahta R
Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
[TBL] [Abstract][Full Text] [Related]
18. Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.
García-Goñi M; Río-Álvarez I; Carcedo D; Villacampa A
Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33918795
[TBL] [Abstract][Full Text] [Related]
19. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
Grewal S; Ramsey S; Balu S; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
[TBL] [Abstract][Full Text] [Related]
20. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
